UCMSCs
Phase 1Cell therapy
UCMSCs is one of 66 biologic programs targeting Bronchopulmonary Dysplasia. It is currently in Phase 1.
3
Indications
6
Total Trials
1
Active Trials
65
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Calciferol
Alnylam PharmaceuticalsPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Rayaldee
OOrganon and Co
Preclinical
Statins
SanofiPreclinical
UCMSCs
SSouth China Research Center for Stem Cell and Regenerative Medicine
Phase 1
Olokizumab
UCBPreclinical
Conventional
PPopulation Health Research Institute
Preclinical
Blood Taken
HHospices Civils de Lyon
Preclinical
Standard Preparation
LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Preclinical
Moderna COVID-19 Vaccine
ModernaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
COVID-191 trial
Mesenchymal Stem Cells1 trial
Efficacy1 trial
Safety and Exploratory Efficacy Study of UCMSCs in Patients With Fracture and Bone Nonunion
Unknown status·SSouth China Research Center for Stem Cell and Regenerative Medicine·Phase 1/2·NCT02815423·40 enrolled
Alzheimer's Disease1 trial
Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease
Unknown status·SSouth China Research Center for Stem Cell and Regenerative Medicine·Phase 1/2·NCT02672306·16 enrolled
1 more indication
Bronchopulmonary Dysplasia1 trial
Intratracheal Umbilical Cord-derived Mesenchymal Stem Cells for Severe Bronchopulmonary Dysplasia
Unknown status·—·Phase 1·NCT01207869·10 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for UCMSCs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details